People: International Stem Cell Corp (ISCO.PK)

ISCO.PK on OTC Markets Group

0.29USD
22 May 2013
Price Change (% chg)

$-0.00 (-1.67%)
Prev Close
$0.30
Open
$0.30
Day's High
$0.30
Day's Low
$0.25
Volume
202,972
Avg. Vol
121,937
52-wk High
$0.45
52-wk Low
$0.16

Search Stocks

Summary

Name Age Since Current Position

Andrey Semechkin

 52 2012 Chairman of the Board, Chief Executive Officer

Jay Novak

 47 2013 Interim Chief Financial Officer

Ruslan Semechkin

 27 2008 Chief Executive Officer & Vice President of Lifeline Skin Care, Inc., Director

Jeffrey Janus

 56 2012 Chief Executive Officer & President of Lifeline Cell Technology

James Berglund

 77 2012 Independent Director

Charles Casamento

 66 2010 Independent Director

Paul Maier

 65 2007 Independent Director

Donald Wright

 60 2007 Independent Director
» Insider Trading

Biographies

Name Description

Andrey Semechkin

 Dr. Andrey Semechkin, Ph.D., is Chairman of the Board, Chief Executive Officer of International Stem Cell Corp. He has been a director of the Company since December 2008. Dr. Semechkin is a specialist in system analysis, strategic planning and corporate management. He is a member of the Russian Academy of Sciences and has been Deputy Director of Institute of System Analysis from 2004 to 2011. Professor Semechkin was awarded the Russian Government Award in Science and Technology in 2006 and has written several scientific books. He has over 20 years experience creating and managing businesses across different industries and scientific sectors.

Jay Novak

 Mr. Jay Novak has been appointed as Interim Chief Financial Officer of International Stem Cell Corp., effective April 16, 2013. Mr. Novak has over 18 years of experience in finance and accounting. He joined the Company in July 2011 and has been serving as Director of Finance since May 2012. Prior to joining the Company, Mr. Novak served as Financial Reporting Manager at Volcano Corporation, a medical device company, from April 2010 to June 2011, as a financial consultant from September 2009 until March 2010, and as Associate Director of Finance at Nanogen, Inc. from April 2007 until August 2009. He previously served as Associate Director of Finance at Elan Pharmaceuticals and as Assistant Director of Finance at Isis Pharmaceuticals. He is a certified public accountant, having begun his career with Deloitte & Touche, LLP. He received a B.S. in Accountancy from California State University, Long Beach, and an MBA from University of California, Irvine.

Ruslan Semechkin

 Dr. Ruslan Semechkin, Ph.D., is Director of International Stem Cell Corporation and Chief Executive Officer & Vice President of Lifeline Skin Care, Inc., a subsidiary of the company. Dr. Semechkin was trained in medical genetics, stem cell biology and international business administration, and holds an M.S. degree from Faculty of Fundamental Medicine of Moscow State University. He earned his Ph.D. degree in Physiology from Anokhin Research Institute of Normal Physiology, Russian Academy of Medical Sciences. Dr. Semechkin is a well-known speaker on stem cell biology, including the use of stem cells for neurology and skin regeneration. He has publications in the field of clinical and molecular biology, and is author of various patent applications.

Jeffrey Janus

 Mr. Jeffrey D. Janus serves as of International Stem Cell Corp., and Chief Executive Officer & President of Lifeline Cell Technology, a wholly- owned subsidiary of the company. He resigned from the Company’s Board of Directors effective August 1, 2012. From 2004 to the present Mr. Janus held the position of president of ISCO. Mr. Janus was appointed the CEO of Lifeline Cell Technology, LLC in January 2004. From 2002 to 2004 Mr. Janus was the Founder and President of Janus Biologics, LLC (Frederick Maryland). From 1998 to 2002 Mr. Janus was Director of Marketing of Human Cell Systems at BioWhittaker Corporation, a Cambrex Company (Walkersville, Maryland) where he expanded the company’s research products portfolio into new fields, including stem cells, and created and implemented the strategy of moving human cell-based research products into the clinical markets. From 1989 through 1998 Mr. Janus played alternate roles as CFO and Director of Marketing in the founding and building of Clonetics Corporation (San Diego, California). Mr. Janus led the product development and marketing of the Clonetics brand, consisting of over 200 human cell and reagent products. The Clonteics brand ultimately captured the share of the domestic and international market in its field, maintained profitability and an annual growth rate of 20 percent for over ten consecutive years. Mr. Janus ultimately implemented the sale of Clonetics to BioWhittaker. None of the prior companies Mr. Janus worked with were affinities of ISCO. Mr. Janus is published in the embryonic stem cell field as a member of a team of international scientists that created the first human parthenogenetic stem cells and in the use of human somatic cells for toxicity applications. Mr. Janus obtained an MBA from San Diego State University and a Bachelors of Science degree in Biochemistry from the University of California at Davis.

James Berglund

 Mr. James H. Berglund is Independent Director of International Stem Cell Corp. He became Director in March 2012. He recently retired as a General Partner from Enterprise Partners Venture Capital, which he cofounded in 1985. At Enterprise Partners, Berglund was mainly involved with healthcare and information technology companies. He currently serves on the board of directors of several private companies and manages a private investment portfolio in a wide range of businesses. His current board activity is a continuation of previous work on more than forty for-profit boards of directors and a number of philanthropic and community boards. Dr. Berglund spent the early years of his career in the areas of eye care and eye care products. Prior to Enterprise Partners, Berglund was President and board member of Continuous Curve Contact lenses, Inc., a public San Diego company later acquired by Revlon. Before moving to San Diego, he was President and board member of Central Laboratories, Inc. and subsequently General Manager of the Contact Lens Division of American Optical Corporation after it acquired Central Laboratories. Prior to his involvement in these business activities, Dr. Berglund was in private Optometric practice. He holds a Bachelors of Science degree in Economics, from the University of Wisconsin and a Doctorate in Optometry from Pacific University. He has also served in the United States Army.

Charles Casamento

 Mr. Charles J. Casamento, is an Independent Director of International Stem Cell Corporation. He has been a director since June 2010. Mr. Casamento is currently Executive Director and Principal of The Sage Group, a healthcare advisory group specializing in mergers, acquisitions, and partnerships between biotechnology companies and pharmaceutical companies. He was the president and CEO of Osteologix, Inc., a public biopharmaceutical company developing products for treating osteoporosis, from 2004 through 2007. From 1999 through 2004, he served as chairman of the board, president and CEO of Questcor Pharmaceuticals, Inc. Mr. Casamento formerly served as RiboGene, Inc.’s president, CEO and chairman of the board from 1993 through 1999 until it merged with Cypros to form Questcor. He was co-founder, president and CEO of Interneuron Pharmaceuticals, Inc. (Indevus), a biopharmaceutical company, from 1989 until 1993. Mr. Casamento has also held senior management positions at Genzyme Corporation, where he was senior vice president, pharmaceuticals and biochemicals; American Hospital Supply, where he was vice president of business development and strategic planning for the Critical Care Division; Johnson & Johnson, Hoffmann-LaRoche, Inc. and Sandoz Inc. Mr. Casamento also serves on the Boards of Directors of CORTEX Pharmaceuticals, SuperGen, Inc. and VIVUS, Inc. He holds a bachelor’s degree in Pharmacy from Fordham University and an M.B.A. from Iona College and was originally licensed to practice pharmacy in the states of New York and New Jersey.

Paul Maier

 Mr. Paul V. Maier serves as an Independent Director of International Stem Cell Corporation. He became a director in July 2007 and has over 20 years of experience as a senior executive in biotechnology and pharmaceutical companies. Since November 2009, he has been serving as Chief Financial Officer of Sequenom, Inc., a publicly held company serving the discovery, clinical research, and molecular diagnostics market. From February 2007 until November 2009, he served as an independent financial consultant. Previously, Mr. Maier was Senior Vice President and Chief Financial Officer of Ligand Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, a position he held from 1992 to 2007. From 1990 to 1992, Mr. Maier served as Vice President, Finance of DFS West, a division of DFS Group, LP a private multinational retailer. From 1984 to 1990, Mr. Maier was employed by ICN Pharmaceuticals, a pharmaceutical and biotechnology research products company, where he held various executive positions in finance and general management in ICN as well as SPI Pharmaceuticals, a publicly held subsidiary. Mr. Maier currently serves on the Board of Directors of both Pure Bioscience and Talon Therapeutics. Mr. Maier received an MBA from Harvard Business School and a BS from Pennsylvania State University.

Donald Wright

 Mr. Donald A. Wright is an Independent Director of International Stem Cell Corporation. Mr. Wright became a director in March 2007. Mr. Wright was previously the Chairman and Founder of Everett, Washington-based Confluence Capital Group Inc., which provided consulting services to institutional investors, debt holders and public and private companies. On January 1, 2010, Mr. Wright became Chief Executive Officer and President of ISIS, Inc. which provides various services under contract to various agencies of the US Government and armed services. From 1995 until 2006, Mr. Wright was Chief Executive Officer and President of Pacific Aerospace & Electronics, Inc., an engineering and manufacturing company that he helped to found and that designs, manufactures and sells components primarily for the aerospace, defense and transportation industries. The Governance Committee believes that Mr. Wright’s director qualifications include serving on multiple public and private company Boards over the last 35 years, and certification from UCLA’s Anderson School of Business for Directors of Public Companies which included modules on the Finance, Audit, Compensation and Corporate Governance Committees.

Basic Compensation

Name Fiscal Year Total

Andrey Semechkin

 3,089,040

Jay Novak

 --

Ruslan Semechkin

 758,206

Jeffrey Janus

 578,258

James Berglund

 --

Charles Casamento

 --

Paul Maier

 --

Donald Wright

 --
As Of 30 Dec 2011

Options Compensation

Name Options Value

Andrey Semechkin

 0 0

Jay Novak

 0 0

Ruslan Semechkin

 0 0

Jeffrey Janus

 0 0

James Berglund

 0 0

Charles Casamento

 0 0

Paul Maier

 0 0

Donald Wright

 0 0

Insider Trading

Name Shares Traded Price

SEMECHKIN ANDREY

 500,000 $0.20

BERGLUND JAMES H

 162,500 $0.00

WRIGHT DONALD A

 162,500 $0.00

MAIER PAUL V

 162,500 $0.00

CASAMENTO CHARLES J

 162,500 $0.00

X MASTER INC

 8,000,000 $0.25

SEMECHKIN ANDREY

 10,000,000 $0.20

CRAW JOHN SIMON

 125,000 $0.00

SEMECHKIN ANDREY

 8,000,000 $0.25

CRAW JOHN SIMON

 20,000 $0.24

BERGLUND JAMES H

 150,000 $0.00

CASAMENTO CHARLES J

 40,000 $0.00

WRIGHT DONALD A

 65,000 $0.00

MAIER PAUL V

 40,000 $0.00

BERGLUND JAMES H

 40,000 $0.00

ALDRICH KENNETH C

 2,000,000 $0.00
» Full list on Insider Trading
Search Stocks